Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Functions and application of leukocyte immunoglobulin-like receptor B4 to treatment on non-alcoholic fatty liver disease and type 2 diabetes mellitus

A technology for diabetes and fatty liver, applied in preparations, vectors, nucleic acid vectors for in vivo experiments, etc., can solve problems such as unclear effects

Active Publication Date: 2017-03-15
武汉惠康基因科技有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of LILRB4 in physiological and pathological processes remains unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Functions and application of leukocyte immunoglobulin-like receptor B4 to treatment on non-alcoholic fatty liver disease and type 2 diabetes mellitus
  • Functions and application of leukocyte immunoglobulin-like receptor B4 to treatment on non-alcoholic fatty liver disease and type 2 diabetes mellitus
  • Functions and application of leukocyte immunoglobulin-like receptor B4 to treatment on non-alcoholic fatty liver disease and type 2 diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] [Example 1] Fatty liver in mice and type Ⅱ diabetes model (diet induced obesity, DIO) were obtained

[0058] (1) Grouping of experimental animals: 8-week-old, male, WT mice and LILRB4-KO mice were selected and given two special diets, D12942 high-fat diet (High fat diet, HFD) and D12450B low-fat diet (Normal chow , NC) feeding, that is, WT NC group, KO NC group, WT HFD group, KO HFD group, a total of 4 groups.

[0059] (2) The model induces the operation process through high-fat feed:

[0060] WT and KO mice were used to establish DIO models, and phenotype correlation analysis was performed to clarify the role of LILRB4 gene on fatty liver and type Ⅱ diabetes. 8-week-old, male, WT mice and LILRB4-KO mice were selected and fed with two special diets, D12942 high-fat diet (HFD) and D12450B low-fat diet (Normal chow, NC), respectively, WT NC group, KO NC group, WT HFD group, KO HFD group, a total of 4 groups. The food intake of the mice was recorded in detail every week...

Embodiment 2

[0061] [Example 2] Determination of mouse body weight and blood sugar level

[0062] (1) Fasting body weight and food intake detection of mice

[0063] 1) Weight detection.

[0064] ①Fasting: fast the mice to be tested at 8:00 am (without water), and start the experimental operation at 2:00 pm.

[0065] ② Weighing: Weigh at 0 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks respectively. In a small bucket, measure the weight and record the data. Feed amount detection: After the weighing operation is completed, add feed to the mice, and record the amount of feed for the mice on the dynamic electronic balance.

[0066] (2) Fasting blood glucose level detection experiment

[0067] All the mice to be tested were fasted from 8:00 am to 2:00 pm (without water), that is, the experimental operation was started after 6 hours of fasting.

[0068] ① Blood glucose meter preparation: Check the battery of the blood glucose meter (Johnson & Johnson, ONETOUCH, USA), press t...

Embodiment 3

[0073] [Example 3] Glucose tolerance test (intraperitoneal glucose tolerance test, IPGTT)

[0074] In the 11th week of the experiment, the intraperitoneal injection of glucose test (IPGTT) was performed to evaluate the glucose tolerance of the mice.

[0075] (1) Before measuring blood glucose, measure the fasting body weight of the mice, and calculate the injection volume of glucose based on 10 μL / g.

[0076] (2) First detect the fasting blood glucose at 0 minutes before the glucose injection, and inject the glucose solution intraperitoneally quickly after the detection is completed.

[0077] (3) Operation method of intraperitoneal injection: ①Fix the mouse; grab the mouse, grab the tail of the mouse with the little finger and ring finger of the left hand, and grab the neck of the mouse with the other three fingers, so that the head of the mouse is downward, and the The abdomen of the mouse is fully exposed. ②Needle positioning and injection: insert the needle from the side ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses functions and application of an LILRB4 (leukocyte immunoglobulin-like receptor B4) gene to treatment on fatty liver diseases and diabetes. By taking LILRB4 gene knock-out mice and wide type C57 mice as experimental subjects and through high fat diet (HFD) induced obesity mouse models, result shows that compared with the wild type (WT) C57 mice, the weight of the LILRB4-KO mice is not remarkably changed after HFD, but the fasting blood-glucose level of the LILRB4-KO mice is higher than that of the WT mice in the control group and the liver function of the LILRB4-KO mice is remarkably worse than that of the WT mice. Intraperitoneal injection glucose tolerance experiments show that the glucose tolerance of the LILRB4-KO mice is remarkably weakened. The liver weight and liver / weight ratio, the lipid component pathological staining result and the like indicate that the fatty liver lesion of the LILRB4-KO mice in the HFD group is remarkably deteriorated and the lipid accumulation is remarkably increased. Therefore, the LILRB4 can serve as a target for screening medicines for treating the fatty liver and / or the type 2 diabetes mellitus, and an accelerant of the LILRB4 can be used for preparing the medicines for treating the fatty liver and / or the type 2 diabetes mellitus.

Description

technical field [0001] The invention belongs to the field of gene function and application, in particular to a leukocyte immunoglobulin-like receptor (leukocyte ig-like receptor B4, LILRB4) as a target gene in the preparation of prevention, alleviation and / or treatment of fatty liver and / or type II Drug application in diabetes. Background technique [0002] Diabetes is caused by various factors such as genetic factors, immune dysfunction, microbial infection, and mental factors. The body's islet function is reduced, insulin resistance, and finally leads to a series of metabolic disorder syndromes such as sugar, protein, fat, water, and electrolytes. Patients with type 2 diabetes are at significantly increased risk of macrovascular and microvascular complications, including atherosclerosis, coronary heart disease, peripheral vascular disease, hypertension, nephropathy, neuropathy, and retinal disease. Diabetes is the third leading health disease after cancer and cardiovascul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K49/00C12N15/85A01K67/027C12Q1/02
CPCA01K67/0275A01K2217/075A01K2227/105A01K2267/0306A61K49/0008C12N15/85C12N2800/107G01N33/5067
Inventor 李红良张鹏黄赞
Owner 武汉惠康基因科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products